We are experiencing extremely high demand in our Emergency Department. Learn more.

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines. Learn more.

What Is DIPG?

Diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) are tumors for which there is no cure.

Because of where these tumors are located in the brain or spinal cord, complete resection is not possible. Radiation and chemotherapy may improve symptoms and extend life, but the average survival remains approximately 11 months.

The DIPG Research Program at Seattle Children’s focuses on DIPG, DMG and other life-threatening central nervous system (CNS) tumors through:

Comprehensive and coordinated clinical care designed to address each child’s needs and circumstances
Innovative laboratory studies that help us better understand these tumors, predict their behavior and treat them more effectively
Clinical trials of new therapies, including CAR T-cell immunotherapy

Find out more information about the DIPG Research Program.

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.